Esperion rises as partner launches cholesterol drug in Japan

Esperion Therapeutics

21/11/2025 17:06

Updates

** Shares of drug developer Esperion ESPR.O rise 7% to $3.15 during afternoon trading

** Co says it will receive a $90 million payment after its Japanese partner, Otsuka Pharmaceutical, launched cholesterol-lowering drug Nexletol in Japan.

** Otsuka received national approval to sell Nexletol for patients with high cholesterol and certain inherited cholesterol disorders, ESPR says

** ESPR eligible for additional milestones and 15%-30% royalties on Japan sales

** Japan is third-largest market for cardiovascular prevention, ESPR says

** Including session's move, shares up ~44% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))